- Home
- ACRS vs CCRD Comparison
ACRS vs CCRD Comparison
Compare ACRS & CCRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CCRD
- Stock Information
- Founded
- ACRS 2012
- CCRD 1973
- Country
- ACRS United States
- CCRD United States
- Employees
- ACRS N/A
- CCRD N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CCRD
- Sector
- ACRS Health Care
- CCRD
- Exchange
- ACRS Nasdaq
- CCRD Nasdaq
- Market Cap
- ACRS 198.2M
- CCRD 210.2M
- IPO Year
- ACRS 2015
- CCRD N/A
- Fundamental
- Price
- ACRS $1.89
- CCRD N/A
- Analyst Decision
- ACRS Strong Buy
- CCRD Hold
- Analyst Count
- ACRS 9
- CCRD 1
- Target Price
- ACRS $9.25
- CCRD $21.00
- AVG Volume (30 Days)
- ACRS 1.1M
- CCRD 35.5K
- Earning Date
- ACRS 11-05-2025
- CCRD 10-30-2025
- Dividend Yield
- ACRS N/A
- CCRD N/A
- EPS Growth
- ACRS N/A
- CCRD 432.93
- EPS
- ACRS N/A
- CCRD 0.99
- Revenue
- ACRS $16,789,000.00
- CCRD $64,808,000.00
- Revenue This Year
- ACRS N/A
- CCRD $17.35
- Revenue Next Year
- ACRS $7.02
- CCRD N/A
- P/E Ratio
- ACRS N/A
- CCRD $26.79
- Revenue Growth
- ACRS N/A
- CCRD 23.61
- 52 Week Low
- ACRS $1.05
- CCRD $12.12
- 52 Week High
- ACRS $5.17
- CCRD $31.99
- Technical
- Relative Strength Index (RSI)
- ACRS 48.51
- CCRD N/A
- Support Level
- ACRS $1.81
- CCRD N/A
- Resistance Level
- ACRS $1.94
- CCRD N/A
- Average True Range (ATR)
- ACRS 0.09
- CCRD 0.00
- MACD
- ACRS -0.01
- CCRD 0.00
- Stochastic Oscillator
- ACRS 27.51
- CCRD 0.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CCRD CoreCard Corporation
CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.